Improvement of Platelet Dysfunction in Chronic Myelogenous Leukemia with Imatinib
Author Information
Author(s): Shimabukuro-Vornhagen Alexander, Rothe Achim, Nogova Lucia, Kochanek Matthias, Scheid Christoph, Bergwelt-Baildon Michael
Primary Institution: Department I of Internal Medicine, University Hospital Cologne
Hypothesis
Treatment targeting BCR-ABL would be equally effective in reducing the CML blasts and dysfunctional megakaryocytes.
Conclusion
Platelet dysfunction and bleeding disorder in BCR-ABL+ chronic myeloid leukemia can successfully be treated with imatinib.
Supporting Evidence
- Imatinib treatment led to a significant improvement in platelet function.
- The patient achieved complete molecular remission six months after treatment.
- Monitoring platelet function is suggested for future studies using imatinib.
Takeaway
A man with a blood disorder had serious bleeding problems, but after taking a medicine called imatinib, his bleeding stopped and he got better.
Methodology
Case report detailing the clinical course and treatment of a patient with chronic myelogenous leukemia and associated platelet dysfunction.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
32-year-old Caucasian man.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website